Market Research Logo

HIV 1 Integrase (EC 2.7.7.) - Pipeline Review, H2 2016

HIV 1 Integrase (EC 2.7.7.) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘HIV 1 Integrase (EC 2.7.7.) - Pipeline Review, H2 2016’, provides in depth analysis on HIV 1 Integrase (EC 2.7.7.) targeted pipeline therapeutics.

The report provides comprehensive information on the HIV 1 Integrase (EC 2.7.7.) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in HIV 1 Integrase (EC 2.7.7.) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.
  • Updated report will be delivered in 48 hours of order confirmation.
Scope
  • The report provides a snapshot of the global therapeutic landscape for HIV 1 Integrase (EC 2.7.7.)
  • The report reviews HIV 1 Integrase (EC 2.7.7.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in HIV 1 Integrase (EC 2.7.7.) targeted therapeutics and enlists all their major and minor projects
  • The report assesses HIV 1 Integrase (EC 2.7.7.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to HIV 1 Integrase (EC 2.7.7.) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for HIV 1 Integrase (EC 2.7.7.)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding HIV 1 Integrase (EC 2.7.7.) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
HIV 1 Integrase (EC 2.7.7.) Overview
Therapeutics Development
HIV 1 Integrase (EC 2.7.7.) - Products under Development by Stage of Development
HIV 1 Integrase (EC 2.7.7.) - Products under Development by Therapy Area
HIV 1 Integrase (EC 2.7.7.) - Products under Development by Indication
HIV 1 Integrase (EC 2.7.7.) - Pipeline Products Glance
Late Stage Products
Early Stage Products
HIV 1 Integrase (EC 2.7.7.) - Products under Development by Companies
HIV 1 Integrase (EC 2.7.7.) - Products under Development by Universities/Institutes
HIV 1 Integrase (EC 2.7.7.) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
HIV 1 Integrase (EC 2.7.7.) - Companies Involved in Therapeutics Development
Critical Outcome Technologies Inc
Gilead Sciences Inc
Merck & Co Inc
TGV-Laboratories
ViiV Healthcare Ltd
HIV 1 Integrase (EC 2.7.7.) - Drug Profiles
(bictegravir sodium +emtricitabine + tenofovir alafenamide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(dolutegravir sodium + rilpivirine hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotide to Inhibit HIV-I Integrase for HIV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cabotegravir sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cabotegravir sodium + rilpivirine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elvitegravir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-522 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-532 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-2048 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit HIV-1 Integrase for HIV infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Integrase for HIV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit HIV-1 Integrase for HIV-1 Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T-169 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIV 1 Integrase (EC 2.7.7.) - Dormant Projects
HIV 1 Integrase (EC 2.7.7.) - Discontinued Products
HIV 1 Integrase (EC 2.7.7.) - Featured News & Press Releases
Nov 18, 2016: ViiV Healthcare launches phase III programme to evaluate a long-acting, injectable HIV treatment regimen
Jul 26, 2016: SMILE Trial Launch - investigating a potentially lower toxicity, simplified treatment regimen for HIV infected children
Feb 24, 2016: ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir
Feb 23, 2016: ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment
Nov 03, 2015: ViiV Healthcare announces positive headline results from a study of two drug injectable regimen for HIV maintenance therapy
May 06, 2015: ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV maintenance therapy
Apr 15, 2015: Critical Outcome Technologies Receives First U.S. Patent For Next Generation HIV Treatment
Jan 15, 2015: Long-acting drug effectively prevents HIV-like infection in monkeys
Apr 21, 2014: Gilead Sciences’ New Drug Applications for Elvitegravir for HIV Therapy Accepted by U.S. FDA
Nov 18, 2013: European Commission Approves Gilead’s Vitekta, an Integrase Inhibitor for the Treatment of HIV-1 Infection
Sep 19, 2013: Gilead Sciences Receives CHMP Positive Opinion For Vitekta For Treatment Of Human Immunodeficiency Virus-1 Infection In Adults
Jul 03, 2013: Monthly Injections With GSK And J&J's Combination Therapy Sustained Drug Levels In Blood To Control HIV, Study Shows
Apr 29, 2013: Gilead Sciences Receives Complete Response Letter From FDA For Elvitegravir
May 20, 2010: Critical Outcome Technologies Inc. Discovers Novel Scaffolds For Inhibiting HIV Integrase
Apr 13, 2010: Critical Outcome Technologies Inc. Provides Update On HIV-1 Integrase Co-Development Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Critical Outcome Technologies Inc, H2 2016
Pipeline by Gilead Sciences Inc, H2 2016
Pipeline by Merck & Co Inc, H2 2016
Pipeline by TGV-Laboratories, H2 2016
Pipeline by ViiV Healthcare Ltd, H2 2016
Dormant Projects, H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report